Latest News

Dongfeng Motor Group (SEHK:489) has just been dropped from the FTSE All-World Index (USD). This index change can affect how some global funds treat the stock in their portfolios. See our latest analysis for Dongfeng Motor Group. Recent moves in Dongfeng Motor Group’s share price have been mixed, with an 8.4% 90 day share price return alongside a very large 3 year total shareholder return of about 3x. This suggests longer term momentum remains strong even as the latest index change and...

Korn Ferry recently reported third-quarter fiscal 2026 results showing year-over-year growth in revenue to US$725.04 million and higher net income of US$65.27 million, alongside guidance for fourth-quarter fee revenue of US$730 million to US$750 million and diluted EPS of US$1.34 to US$1.40. The company also approved a 15% increase in its quarterly dividend to US$0.55 per share, signaling confidence in its cash generation while adding former Deloitte U.S. COO Pete Shimer to its board,...

Prysmian (BIT:PRY) closed out FY 2025 with fourth quarter revenue of €5.3b and basic EPS of €0.82, while trailing twelve month revenue reached €20.1b and EPS came in at €4.32, underpinned by net income from ongoing operations of €1.2b. The company has seen revenue move from €17.1b to €20.1b over the last reported twelve month periods, with EPS rising from €2.59 to €4.32 and trailing net profit margin lifting from 4.3% to 6.2%. This puts profitability squarely in focus for investors assessing...

Enghouse Systems Limited reported past first-quarter 2026 results with revenue of C$120.1 million and net income of C$17.5 million, down from the prior year, while also updating on its completed C$13.8 million share buyback program covering 1.2% of shares. Despite lower revenue and earnings, Enghouse increased its quarterly dividend for the 18th consecutive year and emphasized cash generation, AI initiatives, and capital returns. We’ll now examine how Enghouse’s dividend increase and...

Buyback announcement puts Pulse Seismic in focus Pulse Seismic (TSX:PSD) is back on investors radars after receiving Toronto Stock Exchange approval to renew its normal course issuer bid, along with a new automatic share purchase plan to support share repurchases. See our latest analysis for Pulse Seismic. The renewed buyback comes after a sharp run in the share price, with a 30 day share price return of 21.41% and 90 day share price return of 57.09%. The 1 year total shareholder return of...

Earlier this month, the Australian government temporarily relaxed petrol sulphur limits and released strategic fuel reserves for 60 days, allowing Ampol’s Lytton refinery to sell 50ppm petrol domestically to help stabilise national fuel supply. This short-term regulatory flexibility may enable Ampol to run Lytton harder and reduce reliance on higher-cost premium imports, potentially supporting refinery utilisation and margins while the measure remains in place. We’ll now examine how this...

To help you decide whether Graphic Packaging Holding might offer value at today’s price, this article focuses squarely on what the current share price implies about the company. Recently, the stock has been weak, with returns of 9.7% over 7 days, 21.7% over 30 days, 35.8% year to date, and 61.8% over the last year, which may indicate that expectations and risk perceptions have shifted. These moves come as the company continues to attract attention in packaging, where investors often weigh...

First Bancorp (NasdaqGS:FBNC) announced the retirement of Michael G. Mayer from his roles as President and CEO of First Bank. Mayer is stepping back from day to day management but will continue to serve on the company’s Board of Directors. The change marks a leadership transition at the top of First Bank’s operating structure. First Bancorp, the holding company for First Bank, operates as a regional banking platform, offering lending, deposit, and related financial services. Leadership...

George Weston Limited recently reported fourth-quarter and full-year 2025 results, showing higher sales of CA$16,536 million for the quarter and CA$64,511 million for the year, but lower net income of CA$290 million for the quarter and CA$1,142 million for the year compared with the prior year, alongside a regular quarterly dividend declaration of CA$0.2979 per share and completion of a CA$828.24 million share buyback program that retired 6,950,716 shares. This combination of rising...

Trisura Group (TSX:TSU) has drawn fresh attention after announcing plans to issue CA$200 million of senior unsecured notes. This financing move could influence its balance sheet structure and future capital flexibility. See our latest analysis for Trisura Group. Trisura Group’s CA$44.02 share price has seen a 10.91% 90 day share price return and a 3.31% year to date share price return. The 1 year total shareholder return of 33.92% suggests momentum has been building, with the new CA$200...

RTL Group (XTRA:RRTL) is back in focus after its 2025 results showed sales of €6,018 million and net income of €979 million, alongside an update on its recently completed share buyback program. See our latest analysis for RTL Group. The earnings release and completion of the buyback appear to have kept interest in RTL Group alive, with a 90 day share price return of 13.26% and a 1 year total shareholder return of 12.96% suggesting building momentum rather than a short term spike. If this...

Worldline SA recently completed the launch of a roughly €392 million share capital increase via a rights issue with preferential subscription rights, supported by a broad banking syndicate and key shareholders, as part of a wider approximately €500 million balance sheet strengthening plan. This capital raise, tied to Worldline’s North Star 2030 roadmap and reinforced by an extended payments partnership with ABN AMRO, underlines management’s focus on funding long-term payment infrastructure...

Certara (CERT) is back on investors’ radar after closing 2025 with revenue of US$418.8m, a small net loss, and fresh FDA validation of its biosimulation platform through PBPK modeling used in the asciminib NDA. See our latest analysis for Certara. Despite FDA validation for its PBPK work and new software launches, Certara’s share price has been under pressure, with a 90 day share price return of 23.91% and a 1 year total shareholder return of 39.10%. This may indicate fading momentum after...

Aroundtown (XTRA:AT1) has drawn fresh attention after reporting full year 2025 earnings, issuing 2026 guidance and announcing a proposed €0.08 per share dividend for approval at the June 24, 2026 annual meeting. See our latest analysis for Aroundtown. The recent 1 day share price return of a 3.16% decline, alongside a 30 day share price return of a 16.49% decline, suggests momentum has been fading despite a 3 year total shareholder return of 19.52% that contrasts with a 5 year total...

Westshore Terminals Investment (TSX:WTE) closed out FY 2025 with Q4 revenue of $69.1 million and basic EPS of $0.65, while trailing 12 month revenue came in at $323.0 million and basic EPS at $1.47. The company has seen quarterly revenue move from $110.9 million in Q4 2024 to $69.1 million in Q4 2025, with basic EPS shifting from $0.52 to $0.65 over the same period. With net income of $40.4 million in the latest quarter and trailing 12 month net margin in the high twenties, investors may...

Event context for Wealthfront stock Wealthfront (WLTH) has drawn fresh attention after recent trading left the share price at US$7.86, with short term returns mixed and a value score of 4 prompting closer inspection from investors. See our latest analysis for Wealthfront. That recent 1 day share price return of 0.25% and 7 day share price return of 7.42% sit against a 90 day share price return of 43.66% and year to date share price return of 40.54%, suggesting momentum has been fading even...

Clarity Pharmaceuticals recently reported that its pivotal Phase III AMPLIFY trial for prostate cancer imaging agent 64Cu-SAR-bisPSMA has now consented more than the planned number of participants in the US and Australia, and has stopped new consents pending final enrolment confirmation. This rapid completion of participant consent, building on data from earlier COBRA and Co-PSMA studies, underscores strong clinical interest in 64Cu-SAR-bisPSMA as Clarity pursues potential FDA approval for a...

National Beverage Corp. recently reported past third-quarter results showing sales of US$264.59 million and net income of US$41.21 million, with basic and diluted earnings per share of US$0.44, slightly higher than a year earlier despite modestly lower revenue. The company also cited a 7% increase in January shipments and encouraging early fourth-quarter volume trends, suggesting that new product introductions and its decision not to fully pass through tariffs to consumers are helping...

If you are wondering whether Sirius XM Holdings is still worth a place in your portfolio at today’s price, this article walks through what the current market valuation might be implying. The stock recently closed at US$21.99, with returns of 3.3% over the past 30 days, 7.2% year to date, 2.0% over the last year, and longer term 3 year and 5 year returns of 32.5% and 56.9% declines respectively. This tells a very different story depending on your time frame. Recent coverage has focused on...

Terns Pharmaceuticals recently attracted renewed attention after updating its corporate presentation with refreshed pipeline timelines and milestones, while also being selected for inclusion in a STOXX benchmark index effective March 23, 2026. This combination of clearer development visibility, impending index inclusion, and investor focus on the upcoming earnings update has sharpened debate around the company’s long-term prospects and current financial pressures. With investors now closely...

Earlier this month, Zealand Pharma reported positive topline Phase 2 ZUPREME-1 results showing petrelintide achieved statistically significant, clinically meaningful weight loss with tolerability similar to placebo in people living with overweight and obesity. The data suggest petrelintide’s once-weekly amylin-based profile could offer a differentiated, potentially more tolerable alternative to existing peptide weight-loss therapies, reinforcing Zealand’s obesity franchise with Roche. We’ll...

North American Construction Group Ltd. recently reported full-year 2025 results showing sales rising to C$1,284.29 million while net income fell to C$33.83 million, alongside a quarterly dividend declaration of C$0.12 per share, updated 2026 revenue guidance of C$1.5–C$1.7 billion, and completion of a 407,616‑share buyback. These results highlight a tension between higher revenue and weaker earnings, as project cost adjustments, weather-related disruptions, major Australian contract wins,...

On 9 March 2026, Kelun-Biotech and Harbour BioMed announced that China’s NMPA approved the IND application for SKB575/HBM7575, a long-acting bispecific antibody for atopic dermatitis with a dual TSLP-based mechanism and extended half-life enabling subcutaneous dosing. This IND approval highlights Kelun-Biotech’s growing capabilities in innovative biologics and positions SKB575/HBM7575 as a potentially differentiated long-interval therapy candidate in atopic dermatitis. We will now examine...

In March 2026, Codexis reported fourth-quarter 2025 results showing revenue of US$38.92 million and net income of US$9.6 million, reversing a prior-year loss and beating analyst expectations, alongside full-year 2025 revenue of US$70.39 million and guidance for 2026 revenue of US$72 million to US$76 million. The quarter was heavily influenced by a large technology transfer agreement with Merck and growing ECO Synthesis platform activity, which also underpins management’s view that existing...